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Abstract
BACKGROUND—Biomarkers may play an important role in identifying patients at risk for 
cancer therapy cardiotoxicity. Our objectives were to define the patterns of change in biomarkers 
with cancer therapy and their associations with cardiotoxicity.
METHODS—In a multicenter cohort of 78 breast cancer patients undergoing doxorubicin and 
trastuzumab therapy, 8 biomarkers were evaluated at baseline and every 3 months over a 
maximum follow-up of 15 months. These biomarkers, hypothesized to be mechanistically relevant 
to cardiotoxicity, included high-sensitivity cardiac troponin I (hs-cTnI), high-sensitivity C-reactive 
protein (hsCRP), N-terminal pro–B-type natriuretic peptide (NT-proBNP), growth differentiation 
factor 15 (GDF-15), myeloperoxidase (MPO), placental growth factor (PlGF), soluble fms-like 
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tyrosine kinase receptor-1 (sFlt-1), and galectin 3 (gal-3). We determined if biomarker increases 
were associated with cardiotoxicity at the same visit and the subsequent visit over the entire course 
of therapy. Cardiotoxicity was defined by the Cardiac Review and Evaluation Criteria; alternative 
definitions were also considered.
RESULTS—Across the entire cohort, all biomarkers except NT-proBNP and gal-3 demonstrated 
increases by 3 months; these increases persisted for GDF-15, PlGF, and hs-cTnI at 15 months. 
Increases in MPO, PlGF, and GDF-15 were associated with cardiotoxicity at the same visit [MPO 
hazard ratio 1.38 (95% CI 1.10–1.71), P = 0.02; PlGF 3.78 (1.30–11.0), P = 0.047; GDF-15 1.71 
(1.15–2.55), P = 0.01] and the subsequent visit. MPO was robust to alternative outcome 
definitions.
CONCLUSIONS—Increases in MPO are associated with cardiotoxicity over the entire course of 
doxorubicin and trastuzumab therapy. Assessment with PlGF and GDF-15 may also be of value. 
These findings motivate validation studies in additional cohorts.
The use of anthracyclines and trastuzumab (Herceptin®) have led to improvements in breast 
cancer survival but are also associated with an increased risk of cardiovascular toxicity, 
including left ventricular ejection fraction (LVEF) decline,7 cardiomyopathy, and heart 
failure (HF) (1, 2). Trastuzumab is associated with a 2.5-fold increased risk of 
cardiotoxicity, and the risk is even higher with prior anthracycline exposure (3, 4). Despite 
the severity of the problem, however, few diagnostic tools can be used to identify or predict 
which patients will experience cardiotoxicity. Recognizing at-risk patients before potentially 
irreversible cardiac injury or overt HF could lead to the early initiation of cardioprotective 
strategies, prevent dose interruptions and delays in cancer therapy, and reduce 
cardiovascular and oncologic morbidity.
Some of the first studies of biomarkers in cardiooncology demonstrated that individuals with 
increases in cardiac troponin and natriuretic peptides during chemotherapy were more likely 
to experience cardiotoxicity over the subsequent 12 months (5–7). Recently, we reported an 
association between early increases (baseline to 3 months) in high-sensitivity cardiac 
troponin I (hscTnI) and myeloperoxidase (MPO) in breast cancer patients receiving 
anthracyclines and trastuzumab and the risk of a first cardiotoxic event (8). That study 
evaluated the changes in biomarkers exclusively during anthracycline chemotherapy and 
considered the only first cardiotoxic event for each individual patient. Here, we add to our 
earlier findings by examining whether increases in potentially mechanistic biomarkers 
across the entire course of anthracycline and trastuzumab therapy are associated with a 
cardiotoxic event, also evaluated over the entire course of therapy.
To address this question, we studied the temporal changes in 8 biomarkers measured at 3-
month intervals during doxorubicin and trastuzumab therapy, for a maximum follow-up time 
of 15 months, and defined their associations with cardiotoxicity, occurring either 
concurrently or at a subsequent visit. These biomarkers were particularly relevant, as there is 
7Nonstandard abbreviations: LVEF, left ventricular ejection fraction; HF, heart failure; hscTnI, high-sensitivity cardiac troponin I; 
MPO, myeloperoxidase; hsCRP, high-sensitivity C-reactive protein; GDF-15, growth differentiation factor 15; NT-proBNP, N-
terminal pro–B-type natriuretic peptide; PlGF, placental growth factor; sFlt-1, soluble fms-like tyrosine kinase receptor 1; gal-3, 
galectin 3; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; HERA, Herceptin Adjuvant Trial.
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evidence suggesting they reflect key aspects of the diverse biologic perturbations that occur 
with doxorubicin and trastuzumab cardiotoxicity (9–11). Proposed mechanisms of 
cardiotoxicity exist, with some studies suggestive of an important role for oxidative stress, 
inflammation, and vascular remodeling (11–13). Human clinical studies also demonstrate 
that cardiac injury and abnormal neurohormonal activation occur with these agents (5–7). 
Our panel thus included the following pathways and markers: cardiomyocyte injury (hs-
cTnI); inflammation [high-sensitivity C-reactive protein (hsCRP) and growth differentiation 
factor 15 (GDF-15)]; neurohormonal activation [N-terminal pro–B-type natriuretic peptide 
(NT-proBNP)]; oxidative stress (MPO); antiangiogenesis and vascular remodeling 
[placental growth factor (PlGF) and soluble fms-like tyrosine kinase receptor 1 (sFlt-1)]; and 
fibrosis [galectin 3 (gal-3)].
Materials and Methods
STUDY POPULATION
Eligible patients were ≥18 years of age, diagnosed with human epidermal growth factor 
receptor 2 (HER2)-positive breast cancer, and planned for adjuvant therapy with an 
anthracycline-containing regimen followed by taxanes and trastuzumab. Patients were 
recruited from 4 institutions as previously described (8, 14). Patients with baseline LVEF 
<50% or those unable to provide informed consent were excluded.
Six planned study visits occurred at baseline before chemotherapy and every 3 months 
during chemotherapy over 15 months (Fig. 1). Demographics and clinical history were 
recorded at baseline. Transthoracic echocardiograms were obtained at each visit, and blood 
samples were obtained immediately before cancer therapy infusion at 3-month intervals. 
Consistent with all previous analyses, the primary cardiotoxicity end point was defined by 
use of the Cardiac Review and Evaluation Committee definition: a reduction in LVEF of 
≥5% to <55% with symptoms of HF or an asymptomatic reduction in LVEF of ≥10% to 
<55% (15). In sensitivity analyses, an alternative definition of cardiotoxicity including a 
reduction in LVEF ≥10% to <50% was also evaluated (16).
All participants provided informed consent. The study protocol was approved by the 
institutional review boards of the participating institutions.
ECHOCARDIOGRAPHY
Transthoracic echocardiograms were acquired by use of Vivid 7 or E9 (GE Healthcare) and 
analyzed on the EchoPAC workstation (GE Healthcare) (8, 17). Left ventricular end-
diastolic and end-systolic volumes were measured by the Simpson method of discs (18) in 
the apical 4- and 2-chamber views, and LVEF was calculated as follows: (end-diastolic 
volume – end-systolic volume)/enddiastolic volume × 100%. All measurements were made 
at a centralized reading center by a single observer who was blinded to all clinical and 
biomarker data.
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BIOMARKERS
Venous blood was collected in standard tubes for plasma with both EDTA and lithium 
heparin, processed at 3100 rpm for 15 min, divided into aliquots, and stored at −80 °C until 
the time of assay. Measurement of hs-cTnI, a research prototype assay, and NT-proBNP 
were performed on the Dimension Vista 500 Intelligent Laboratory System (Siemens 
Healthcare Diagnostics); hsCRP was measured with a standard Architect immunoassay 
(Abbott Laboratories); and GDF-15, MPO, PlGF, sFlt-1, and Gal-3 were measured with 
prototype Architect chemiluminescent 2-step microparticle-based immunoassays (Abbott 
Laboratories). All measurements were performed on previously unthawed samples. CVs for 
all assays were <10%. Briefly, hs-cTnI had a 10% CV at 3 ng/L; NT-proBNP <3%; hsCRP 
≤6%; GDF-15 ≤4.5%; MPO ≤9.8%; PlGF ≤6.7%; sFlt-1 ≤5.9%; and gal-3 ≤4.5%. Further 
details are in the Supplemental File, which accompanies the online version of this article at 
http://www.clinchem.org/content/vol61/issue9.
STATISTICAL METHODS
Each biomarker was recorded as the ratio of the value at each visit relative to baseline, and, 
for the purpose of modeling, transformed to a log2 scale. Here each unit increase in the 
biomarker ratio represents a doubling in value compared to baseline. Using a Wilcoxon 
signed rank, we determined whether the median of the ratio (original scale) differed from 
1.0 at each time point; the hypothesis tests were Bonferroni corrected for each bio-marker. 
Individual trajectories of biomarker ratios were visualized with a locally smoothed mean.
As in clinical practice, we evaluated the cardiotoxicity outcome at each visit and defined this 
as present or absent. Presence of cardiotoxicity at an individual visit reflected either new or 
persistent cardiotoxicity. We first modeled the outcome as a function of the individual 
biomarker ratio at the same visit (i.e., both the ratio and cardiotoxicity at the 3-month visit, 
both the ratio and cardiotoxicity at the 6-month visit, and so forth to 15 months) (Fig. 1). 
Next, we evaluated the association between each biomarker ratio and cardiotoxicity at the 
subsequent 3-month visit (i.e., the bio-marker ratio at the 3-month visit with cardiotoxicity 
at the 6-month visit, the biomarker ratio at the 6-month visit with cardiotoxicity at the 9-
month visit, and so forth to 15 months). The models were implemented by use of a repeated-
measures Cox model with the biomarker ratios entered into the model as time-varying 
covariates. Information from all visits was incorporated into a single estimated risk and 
expressed as a hazard ratio (HR) per doubling of the biomarker. Significance was evaluated 
with a robust Score test (P < 0.05).
We then constructed a multiple biomarker model that included biomarkers with a P value 
<0.20 in individual models, retaining only those with P < 0.05. For the multivariable model, 
the robust Score test was again used to test global significance. Wald tests were used to 
evaluate individual terms (19). To consider the potential clinical significance of the 
biomarkers, we determined the 75th and the 90th percentiles of the ratios for the bio-markers 
included in the final multivariable model. For each time point, we then determined the 
relative risk of cardiotoxicity for the 2 percentiles compared to the median biomarker ratio.
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We carried out 2 types of sensitivity analyses. To address alternative definitions of 
cardiotoxicity within the field of cardio-oncology, we repeated the modeling procedure with 
the individual covariates but with the Herceptin Adjuvant Trial (HERA) outcome (reduction 
in LVEF ≥10% to <50%). To address possible bias in our estimates due to incomplete data, 
we constructed a dataset in which we used the median across all patients at each time point 
to impute the biomarker concentrations of individuals with missing data and excluded the 
15-month visit, where there was a high rate of missing data. We constructed an additional 
dataset in which we excluded a site where the missing data rates were high. For both 
datasets, we repeated the analyses described above.
A priori, hypothesis tests were specified to be 1-sided, given findings from our prior work 
(8), where only increases in biomarkers were relevant in defining cardiotoxicity risk. For a 
1-sided type 1 error rate of 0.05, a sample size of 78 patients, and an event rate of either 
15% or 30%, a time-to-first-event Cox model would have 80% power to detect relatively 
large HRs, on the order of 1.7–2.1, respectively (PASS 2008). In a repeated-measures Cox 
model, the detectable HRs are expected to be slightly lower. Analyses were performed with 
R 3.03 (R Development Core Team).
Results
STUDY POPULATION
The mean age of these 78 women was 49 years, and the mean body mass index was 24.5 
kg/m2 (Table 1). At time of enrollment, 27% had hypertension, 23% had hyperlipidemia, 
and 9% smoked. At baseline, the mean (SD) LVEF was 64% (5%).
PATTERNS OF CARDIOTOXICITY DURING DOXORUBICIN AND TRASTUZUMAB THERAPY
Over the course of the 15-month study, 23 patients experienced 39 events. Twelve patients 
had a single event, 7 had 2, and 4 had >2 events; these repeated events primarily reflected a 
persistent LVEF decline. Rates of cardiotoxicity were <5% at 3 months and ranged from 
9.3% to 19.1% for the remainder of the study. The first evidence of cardiotoxicity occurred 
most frequently at 6 and 12 months. After the diagnosis of cardiotoxicity, trastuzumab was 
discontinued in 3 patients; 1 was treated with angiotensin-converting enzyme inhibitors and 
beta-blockers; no additional intervention was performed in the other 2 patients.
BIOMARKER CHANGES DURING DOXORUBICIN AND TRASTUZUMAB THERAPY FOR THE 
ENTIRE COHORT
Baseline concentrations of each biomarker appear in Table 2. For the cohort as a whole, all 
biomarkers except gal-3 and NT-proBNP showed significantly increased concentrations at 3 
months compared with baseline (Table 2, online Supplemental Fig. 1). At subsequent visits, 
the concentrations tended to decline, with only GDF-15, PlGF, and hs-cTnI demonstrating 
persistently increased concentrations at 15 months. As shown in Table 2, the median 
concentration for GDF-15 at baseline was 500 ng/L (interquartile range 349–733). 
Compared with baseline, the biomarker concentration at 3 months was 1.6-fold greater, 
decreasing to 1.2-fold at 15 months. In contrast, changes in MPO and PlGF concentrations 
were less pronounced. The median ratio of these 2 biomarkers increased to 1.3 at 3 months, 
Putt et al. Page 5
Clin Chem. Author manuscript; available in PMC 2016 September 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
and then decreased to a ratio of 0.9–1.1 by 15 months. Across patients, MPO showed the 
largest variation; PlGF showed the smallest variation, with PlGF also demonstrating 
moderate to strong correlations (P > 0.50) across all visits.
Interestingly, the median hs-cTnI concentration at baseline was 1.3 ng/L; concentrations 
increased to a median of 9.9-fold that of baseline at 3 months and 12.0 at 6 months (Table 2, 
online Supplemental Fig. 1). In contrast to all other biomarkers, at 15 months, the hs-cTnI 
ratio still remained substantially increased and was 3.9-fold greater than baseline.
ASSOCIATION BETWEEN CHANGES IN INDIVIDUAL BIOMARKERS AND CARDIOTOXICITY 
AT THE SAME VISIT
The association between increases in individual biomarkers, as measured by the log2 
biomarker ratio, and concurrent cardiotoxicity was estimated with a model that evaluated 
biomarker increases at 3 months and cardiotoxicity at 3 months, increases at 6 months and 
cardiotoxicity at 6 months, and so forth. As shown in Table 3, increases in MPO, PlGF, and 
GDF-15 were each individually associated with an increased risk of cardiotoxicity [MPO 
HR 1.37 (95% CI 1.11–1.69), P = 0.02; PlGF 3.77 (1.43–9.89), P = 0.04; GDF-15 1.80 
(1.20–2.69), P = 0.007]. hsCRP was of marginal significance (P = 0.07), and hs-cTnI (P = 
0.30) and NT-proBNP (P = 0.19) were not associated with cardiotoxicity.
In sensitivity analyses, findings were similar when we considered outcomes from 6 months 
onward during trastuzumab therapy alone (data not shown). When we considered alternative 
definitions of cardiotoxicity (reduction in LVEF ≥10% to <50% as described in HERA 
(16)), our findings were similar, with widely overlapping CIs (see online Supplemental 
Table 1). Here, there were only 11 events, and as a result, the power to detect significant 
effects was lower than in the analyses described above. Importantly, in our univariable 
models, increases in MPO [HR 1.72 (95% CI 1.26–2.36), P = 0.04] remained significantly 
associated with cardiotoxicity, and increases in PlGF approached significance [HR 3.32 
(95% CI 0.96–11.56), P = 0.06]. The association between GDF-15 and cardiotoxicity was 
attenuated.
Our second set of sensitivity analyses addressed the issue of incomplete data. At the 3-, 6-, 
and 9-month visits, the proportion of incomplete biomarker data ranged from 8% to 13% for 
all biomarkers except hscTnI; for hs-cTnI, incomplete data rates were 15%–19% at these 
visits. At 12 months, these rates were 19% (all biomarkers but NT-proBNP or hs-cTnI) and 
26%–30% (NT-proBNP and hs-cTnI). At 15 months, these rates increased to 33% and 51%–
54%, respectively.
Importantly, for the question of bias, 1 site in particular had high rates of missing data that 
reflected logistical issues with the site, rather than specific patient characteristics. Excluding 
patients from this site and considering baseline, 3-, 6-, and 9-month visits, the percentage of 
missing biomarker data was only 5% (all biomarkers but NT-proBNP and hs-cTnI), 5%–
12% (NT-proBNP), and 15%–19% (hs-cTnI). At 12 months, data were missing in 11% (all 
biomarkers but NT-proBNP and hs-cTnI) and 21%–23% (NT-proBNP and hs-cTnI) of 
patients. At 15 months, data were missing in 15% (all biomarkers but NT-proBNP and hs-
cTnI) and 38%–41% (NT-proBNP and hs-cTnI).
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To explore the potential impact of these incomplete data on the associations described 
above, we imputed the missing data by use of the median concentration across individuals 
from all sites. We then excluded the 15-month time point and also the 1 site with high rates 
of missing data. For these datasets, our findings were largely similar for GDF-15, MPO, and 
PlGF, with statistical significance maintained for these 3 markers (see online Supplemental 
Table 2). No substantive changes were observed in the results for any other biomarker.
ASSOCIATION BETWEEN CHANGES IN INDIVIDUAL BIOMARKERS AND CARDIOTOXICITY 
AT THE SUBSEQUENT VISIT
Next, we examined the association between changes in biomarkers as measured by the log2 
biomarker ratio and cardiotoxicity at the subsequent visit. The goal of these models was to 
gain insight into cardiotoxicity prediction within a short time window. We found similar 
results for MPO (P = 0.003) and GDF-15 (P = 0.02), with a comparable, albeit not 
statistically significant, effect for PlGF (P = 0.08) (Table 3). Of note, gal-3 was also 
significantly associated with cardiotoxicity at the subsequent visit [HR 1.60 (95% CI 1.12–
2.28), P = 0.04].
When we considered alternative definitions of cardiotoxicity as part of a sensitivity analysis 
(reduction in LVEF ≥10% to <50% (16)), our findings were similar (see online 
Supplemental Table 1). In sensitivity analyses described above, where we imputed the data, 
the results were also very similar (see online Supplemental Table 3).
ASSOCIATIONS BETWEEN CHANGES IN MULTIPLE BIOMARKERS AND CARDIOTOXICITY
Our multivariable models initially included all biomarkers with P < 0.20 in our univariable 
associations (MPO, PlGF, GDF-15, gal-3, NT-proBNP, and hsCRP). For the model with the 
biomarkers and outcome measured at the same visit, the final model (overall P = 0.007) 
included MPO, PlGF, and GDF-15. Risk estimates for the multivariable model were similar 
to those seen in the univariable models (Table 3). Associations between these 3 markers in 
combination and cardiotoxicity at the subsequent visit were also significant (overall P = 
0.02). For both models, the results were very similar after imputation of the incomplete data, 
as shown in online Supplemental Tables 2 and 3 (overall P = 0.02).
Although our models yielded estimates of risk per doubling of each biomarker, we note that 
the potential clinical importance of a biomarker depends not only on this risk estimate, but 
also on the distribution of the ratio at each time point. For example, if 2 biomarkers are 
associated with the same risk, but 1 biomarker has more frequent doublings occurring than 
the other, the first potentially has more clinical impact. Thus, Fig. 2 considers the predicted 
risk of cardiotoxicity for MPO, PlGF, and GDF-15 at the 75th and 90th percentiles of the 
biomarker relative to the median biomarker ratio at the same visit (Fig. 2A) and the 
subsequent visit (Fig. 2B). In each figure, the risk relative to the median biomarker ratio at 
that time point is plotted. For both models, increases in MPO and GDF-15 at the 75th and 
90th percentiles were associated with increases in cardiotoxicity risk of 1.1–1.6 (MPO) and 
1.2–1.6 (GDF-15) compared with the median value for that biomarker. For PlGF, the 
increases were on the order of 1.1–1.3 at the 75th and 90th percentiles across the visits.
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Discussion
This study of breast cancer patients is one of the first to explore the association between 
increases in multiple bio-markers and cardiotoxicity risk over the entire duration of 
doxorubicin followed by trastuzumab therapy. Our previous work (8) examined the 
association between early changes in biomarkers during doxorubicin therapy only (i.e., 3 
months) and the first occurrence of cardiotoxicity. That study identified an association 
between an increase at 3 months in hs-cTnI and MPO and the risk of first cardiotoxicity (8). 
In the present study, we considered repeated biomarker increases for up to 15 months and 
their associations with each cardiovascular event, at either the same visit or the subsequent 
visit 3 months later. Importantly, our present work suggests that increases in MPO beyond 3 
months remain a predictor of cardiotoxicity risk over the duration of doxorubicin/
trastuzumab therapy. In addition, we identify 2 other candidate biomarkers, GDF-15 and 
PlGF, of possible interest. The independence of these markers in our multivariable model 
suggests additive utility.
Before this study, the association and time sequence between the development of 
cardiotoxicity and the increases in biomarkers over the entire course of doxorubicin and 
trastuzumab therapy was unclear. This motivated the 2 sets of models, 1 relating the 
biomarker concentration and cardiotoxicity at a concurrent visit, and 1 relating the 
biomarker concentration and cardiotoxicity at a subsequent 3-month visit. The similarity of 
our results for both models suggests that the associations are temporally robust. With an 
alternative definition of cardiotoxicity, our findings were similar.
Importantly, this study goes beyond our previous work and indicates that increases in MPO 
throughout the course of doxorubicin/trastuzumab therapy are significantly associated with 
cardiotoxicity. MPO is an enzyme secreted by polymorphonuclear leukocytes that is 
proatherogenic and prooxidant (20). It is believed to be a marker of oxidative stress (20), 1 
of the central mechanisms of doxorubicin cardiotoxicity (21), as well as potentially related 
to ErbB2 inhibition by trastuzumab (22, 23). In our study, it is also possible that the MPO 
increases from doxorubicin persisted into the period when trastuzumab was administered. 
Overall, this study adds weight to our previous finding of MPO as a strong candidate 
biomarker of cardiotoxicity in breast cancer patients treated with doxorubicin and/or 
trastuzumab.
We identified 2 additional markers that may be relevant to doxorubicin and trastuzumab 
cardiotoxicity: PlGF and GDF-15. PlGF is a member of the vascular endothelial growth 
factor family and may play an important cardioprotective role through cardiomyocyte and 
endothelial cell paracrine signaling and promotion of angiogenesis (24, 25). As such, it is 
plausible that PlGF may be specifically relevant to the pathophysiology of anthracycline and 
trastuzumab cardiotoxicity, as data suggest these agents affect angiogenesis (26, 27). 
Circulating PlGF has shown to be of prognostic value in preeclampsia, acute coronary 
syndromes, and ischemic cardiomyopathy (28–31).
GDF-15 is a member of the transforming growth factor-β cytokine superfamily, expressed 
by multiple cell types (32, 33), and released in response to ischemia, injury, mechanical 
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stretch, oxidative/nitrosative stress, and inflammation (34). As a biomarker, GDF-15 has 
been associated with increased risk of incident HF, progression, and death (33). Given the 
significant associations and biologic plausibility, these 2 biomarkers are candidates for 
further study.
In contrast to previous work, including our own when we had exclusively evaluated early 
increases in these markers (baseline to 3 months) (8), hs-cTnI and NT-proBNP did not show 
evidence of an association with cardiotoxicity and risk of first cardiotoxic event. In the 
results presented here, we cannot exclude the possibility that insufficient statistical power 
precluded us from detecting an effect, particularly since the hs-cTnI data were missing in a 
larger fraction of observations than the other biomarkers. Alternatively, for the cohort as a 
whole, hscTnI demonstrated a strikingly different pattern from the other biomarkers (Table 
2, online Supplemental Fig. 1). hs-cTnI was substantially more increased at 3 months, and 
unlike other markers, this increase did not resolve by 15 months. We hypothesize that these 
increases in hscTnI might reflect processes that predispose patients to first cardiotoxicity, 
but that there is insufficient resolution of hs-cTnI increase in those who do not experience 
subsequent cardiotoxicity or who resolve cardiotoxicity to allow it to be an effective 
diagnostic biomarker at later time points. We also note that we used a hs-cTnI platform, in 
contrast to other studies (35). Clearly, our work is not definitive; there is a critical need for 
additional studies in larger cohorts and with extended follow-up time to further explore the 
role of hs-cTnI over the duration of chemotherapy.
There are a number of limitations. Our cohort was comprised of 78 patients, of whom 23 
experienced ≥1 cardiotoxicity events. Overall, this number and particularly the number of 
individuals experiencing events are small. With alternative definitions of cardiotoxicity, we 
had only 11 events, further limiting power. The small number of outcomes limits our ability 
to differentiate between biomarker associations that are related to acute or delayed recovery, 
or lack thereof. Moreover, given the number of events and concerns of overfitting our 
models, we did not include potential confounders, such as medication use. The impact of 
confounding thus remains an important question for future studies. Last, our study was 
subject to incomplete data. We cannot rule out the possibility of bias due to these missing 
data, although our sensitivity analyses with the imputed data yielded results that were highly 
consistent with the analyses presented here. Although our work describes results for one of 
the largest cohorts in breast cancer with multiple and serial newer biomarker and 
echocardiographic measures, our findings require independent confirmation.
In conclusion, our results identify several biomarkers that may have clinical relevance to 
patients undergoing sequential therapy with doxorubicin and trastuzumab. In particular, 
assessment of MPO, perhaps in conjunction with PlGF and GDF-15, may improve on the 
identification of breast cancer patients who are at risk for cardiotoxicity with these agents.
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Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Study protocol and analytic approach
Biomarkers, echocardiograms, and questionnaires were obtained at visits 1–6, at 0, 3, 6, 9, 
12, and 15 months (vertical arrows). Biomarkers and cardiotoxicity status were defined at 
each visit; biomarkers were expressed as a ratio relative to baseline (tick marks). Example 
patient with cardiotoxicity at 9 and 15 months shown. Associations between biomarker 
ratios and cardiotoxicity were determined at each concurrent and subsequent visit.
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Fig. 2. Cardiotoxicity risk
Cardiotoxicity risk at each visit for the 75th (▲) and 90th (■) percentiles relative to the 
median (●) for biomarkers of primary interest as derived from multivariable models for the 
same visit (A) and subsequent visit (after 3 months) (B). The numbers below the graph 
indicate the biomarker ratio relative to baseline at the 50th, 75th, and 90th percentiles at the 
same visit (A) or the preceding visit (B).
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Table 1
Baseline patient characteristics (n = 78).a
Characteristic Value
Age, years 49 (10)
Body mass index, kg/m2 25.5 (4.5)
Tobacco user 7 (9)
Breast cancer side
    Left 38 (49)
    Bilateral 6 (8)
Hypertension 21 (27)
Diabetes 1 (1)
Hyperlipidemia 18 (23)
Radiotherapy 46 (60)
Angiotensin-converting enzyme inhibitor 13 (17)
Beta-blocker 10 (13)
LVEF, % 64 (5)
a
Data are n (%) or mean (SD). Adapted with permission from Ky et al. (8).
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Table 2
Biomarker levels at baseline and ratio of biomarkers relative to baseline at each visit.a
Median biomarker level relative to baseline at indicated visit
Biomarker Baseline (0 months) 3 months 6 months 9 months 12 months 15 months
GDF-15, ng/L 500 (349-733) 1.6 1.6 1.3 1.2 1.2
MPO, pmol/L 107 (76.7-173) 1.3 1.0 0.9 0.8 0.9
PIGF, ng/L 19.6 (17.5-23.3) 1.3 1.3 1.2 1.1 1.1
hsCRP, mg/L 1.72 (0.633-3.92) 1.6 1.4 0.9 1.0 0.9
hsTnl, ng/L 1.30 (0.700-3.95) 9.9 12.0 6.8 4.2 3.9
Gal-3, μg/L 13.8 (10.8-18.2) 1.0 1.0 1.0 1.0 1.0
NT-proBNP, ng/L 71 (37.0-133) 0.9 0.7 1.0 1.1 1.2
sFlt-1, ng/L 236 (215-272) 1.1 1.1 1.0 1.0 1.0
a
Data are median (interquartile range). Bold text indicates medians >1.0(P < 0.05). In contrast to this table, Supplemental Figure 1 shows the log-
transformed values as used in the models.
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Table 3
Longitudinal associations between increases in biomarkers relative to baseline and cardiotoxicity.
Risk of cardiotoxicity at the same visit Risk ofcardiotoxicityat the subsequent visit
Univariable Multivariable Univariable Multivariable
Biomarker HR(95%CI) P HR(95%CI) P HR(95%CI) P HR(95%CI) P
GDF-15 1.80 (1.20-2.69) 0.007 2.16 (1.49-3.13) <0.001 1.59 (1.06-2.40) 0.02 1.62 (1.07-2.44) 0.01
MPO 1.37 (1.11-1.69) 0.02 1.31 (1.08-1.60) 0.004 1.32 (1.11-1.58) 0.003 1.30 (1.06-1.58) 0.006
PIGF 3.77 (1.43-9.89) 0.04 3.09 (1.24-7.72) 0.008 2.61 (0.95-7.19) 0.08 3.27 (1.19-8.94) 0.01
hsCRP 1.18 (0.97-1.44) 0.07 1.12 (0.88-1.42) 0.19
hsTnl 1.04 (0.91-1.20) 0.30 1.08 (0.96-1.20) 0.14
GaI-3 1.31 (0.86-1.99) 0.14 1.60 (1.12-2.28) 0.04
NT-proBNP 1.13 (0.86-1.49) 0.19 1.07 (0.83-1.38) 0.31
sFIt-1 1.08 (0.54-2.16) 0.41 0.86 (0.49-1.50) 0.31
Data are median (interquartile range) for a log2 ratio of the biomarker relative to baseline, i.e., for each doubling of the biomarker. All P-value 
shown are 1-sided.
Clin Chem. Author manuscript; available in PMC 2016 September 01.
